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Abstract
Purpose: In the WHO diagnostic classification, prefibrotic myelofibrosis (pre-MF) is included in the category of primary
myelofibrosis (PMF). However, strong evidence for this position is lacking.
Patients and Methods: We investigated whether pre-MF may be aligned along a clinical and biological continuum in 683
consecutive patients who received a WHO diagnosis of PMF.
Results: As compared with PMF-fibrotic type, pre-MF (132 cases) showed female dominance, younger age, higher
hemoglobin, higher platelet count, lower white blood cell count, smaller spleen index and higher incidence of splanchnic
vein thrombosis. Female to male ratio and hemoglobin steadily decreased, while age increased from pre-MF to PMF- fibrotic
type with early and to advanced bone marrow (BM) fibrosis. Likely, circulating CD34+ cells, LDH levels, and frequency of
chromosomal abnormalities increased, while CXCR4 expression on CD34+ cells and serum cholesterol decreased along the
continuum of BM fibrosis. Median survival of the entire cohort of PMF cases was 21 years. Ninety-eight, eighty-one and fifty-
six percent of patients with pre-MF, PMF-fibrotic type with early and with advanced BM fibrosis, respectively, were alive at
10 years from diagnosis.
Conclusion: Pre-MF is a presentation mode of PMF with a very indolent phenotype. The major consequences of this
contention is a new clinical vision of PMF, and the need to improve prognosis prediction of the disease.
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Introduction
Primary myelofibrosis (PMF) is recognized as a distinct clinical
entity among classical Philadelphia-negative myeloproliferative
neoplasms (MPNs) which also include essential thrombocythemia
(ET) and polycythemia vera (PV) [1]. In spite of a wide range of
functional [2] and clinical presentations [3], its uniqueness has
been traditionally grounded on the constitutive association of
reticulin or collagen fibrosis in bone marrow (BM) with
megakaryocyte hyperplasia and dysplasia, and mobilization of
hematopoietic progenitor cells with extramedullary hematopoiesis
[4–6]. In the 90s’, Thiele and co-workers disrupted the dogma of
BM fibrosis being an intrinsic and necessary stigma of PMF, and
they first proposed a new category of patients characterized by
absence of relevant reticulin fibrosis in BM with dual megakar-
yocytic and granulocytic myeloproliferation associated with
characteristic megakaryocyte dysplasia [7–9]. This variant, called
prefibrotic myelofibrosis (pre-MF), has been included as a
prodromic phase of PMF into the WHO classification of MPNs
since 2001 [10], and the criteria for the diagnosis were further
outlined in 2008 [11]. Now, pre-MF has joined the ranks of the
diagnostic categories used in the practice of most of the
hematopathologists worldwide, even though there is still a number
of unresolved issues concerning its diagnostic reproducibility [12–
16], and molecular and biological identity [17–20].
Since the phenotype of pre-MF resembles that of ET, in the last
years the research on the disease has established the stronger
tendency of patients with pre-MF to have bleeding [21], to evolve
into overt PMF and leukemia [22,23], and to have shorter survival
with respect to ET [22,23].
In this paper we aimed to question whether there is an
underlying structure of the patients’ clinical and biological data
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35631that allows to align pre-MF patients along a continuum of
characteristics featuring PMF or to assign it to a separate disease
entity among MPNs. We reasoned that the evidence for pre-MF
being a prodromic phase of PMF is limited to the histological
documentation of a tendency to myelofibrotic progression [7–
9,22,23]. Moreover, the definition of pre-MF in the most recent
studies included both pre-MF with zero grade BM fibrosis and
early myelofibrosis [22,23], i.e. with grade 1 BM fibrosis, thus
mixing two possibly different categories of patients with different
phenotypes and evolutions. Finally, a great deal of evidence on the
natural history of pre-MF derives from series collected from
patients with an initial clinical diagnosis of ET, and this may limit
the spectrum of presentations of pre-MF [22,23]. To this aim, we
will describe the epidemiological, clinical and biological features of
the consecutive cases of pre-MF collected among a large cohort of
patients diagnosed with PMF in our centre after revision of the
diagnostic BM biopsy.
Methods
Ethics Statement
The study was approved by the IRCCS Policlinico S. Matteo
Foundation’s institutional review board. Written informed consent
was obtained from each patient before data were entered in the
database.
Study Cohort
The cohort of patients from whom the cases of pre-MF were
extracted was composed by all consecutive patients seen from
1990 to 2011 in our centre who received a diagnosis of PMF
according to the WHO criteria [10,11]. The cohort was
established after a systematic revision of BM biopsies taken at
diagnosis of near all the MPNs cases observed in our centre.
Data collection
We have collected uniform information about all patients who
have been examined at least once as outpatients or inpatients in
our centre. Information was collected in a retrospective fashion at
the time of first visit, and prospectively thereafter. Patients at
diagnosis had complete blood count and differentials, serum
cholesterol and lactic dehydrogenase (LDH), physical examination
and clinical complications at or preceding diagnosis. Patients
evaluated after the diagnosis had these details reviewed from other
centres. All patients had BM biopsy at diagnosis or had BM
samples taken at diagnosis reviewed by our pathologist (UM). On
this sample, the degree of BM cellularity in paraffin-embedded
BM biopsy specimens stained with hematoxylin and eosin was
estimated. In addition, Gomori stains were applied to paraffin
sections of the BM biopsy specimens and quantitative estimation of
degree of fibrosis was performed according to the EUMNET
criteria [24]. After year 1999, all patients received the enumer-
ation of CD34-positive cells in peripheral blood [6], and the
measurement of CXCR4 expression on circulating CD34-positive
cells [25]. After year 2005, patients received the assessment of
JAK2V617F mutation in their peripheral blood granulocytes [26].
In the great majority of the cases the quantitative allele burden was
also measured [26]. Chromosomal analysis was not systematically
planned, but it was done in few centers and in all patients who
received a BM biopsy in our centre. Abnormal karyotype was
defined by the presence of at least two metaphases with structural
abnormalities or monosomy or three metaphases with polysomy.
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Prefibrotic Myelofibrosis
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35631Diagnosis of prefibrotic myelofibrosis
For classifying a patient as having pre-MF we reinterpreted the
criteria reported in 2001 by the WHO system [10], and we based
the diagnosis on the existence of three bone marrow character-
istics: dual myeloid megakaryocyte dominance, megakaryocyte
morphology (anisocytosis, dense nuclei with plump lobation) with
clustering, and a BM fibrosis grade 0 or less than 1. Patients with
the bone marrow morphological features of pre-MF but having at
least grade 1 fibrosis were categorized into the category of PMF,
fibrotic type.
Statistical Analysis
Categorical variables are presented as frequencies and percent-
ages, and continuous variables as means and standard deviations,
or medians for variables with skewed distribution. Univariate
analyses comparing subject characteristics were done with the t
test for continuous variables, or by non parametric analysis of
variance (Kurskall-Wallis test) or by Mann-Witney U test. The
continuum hypothesis that the patient’s characteristics varied
along three grades of BM fibrosis was tested by verifying if the
means of the ordered groups change in a linear or higher order
fashion (ANOVA with trend).
Logistic regression was used to assess the ability of the patients’
characteristics to predict hematological and biological relevant
parameters. We examined the following covariates: sex, age,
presence of splanchnic vein thrombosis, JAK2V617F mutation.
Logistic models were obtained by performing a backward
elimination with a P value cut-off of .05, and then allowing any
variable previously deleted to enter the final model if its P value
was ,.05. Survival analysis was drawn using the Kaplan-Meier
procedure. Results were considered statistically significant when P
values were less than 0.05. All computations were performed with
STATISTICA software (Statsoft, Tulsa, OK, USA).
Results
Clinical Characteristics of Prefibrotic Myelofibrosis
Among the 683 patients with PMF, 132 fulfilled the criteria we
established for the diagnosis of pre-MF, thus giving an overall
frequency of 19.3%. The clinical characteristics of PMF patients at
diagnosis stratified according to the category of pre-MF and PMF-
fibrotic type are illustrated in Table 1. As compared with patients
with PMF-fibrotic type, patients with pre-MF had significantly
younger age and higher female to male ratio (P,0.001 for each
comparison). Diagnosis of pre-MF occurred at the age of 50 years
or younger in 87%, while in 35.6% (P,0.001) in PMF-fibrotic
type. As compared with patients with PMF-fibrotic type, patients
with pre-MF had higher hemoglobin concentrations (mean
increase, 2.3 g/dL, 95% CI, 1.7–2.8 g/dL; P,0.001), higher
platelet count (mean increase, 218610
9/L, 95% CI, 153–
282610
9/L; P,0.001), lower white blood cell count (mean
decrease, 1.4610
9/L; 95% CI, 0.04–2.8610
9/L; P,0.052), and
smaller spleen index (mean decrease, 63 cm
2; 95% CI, 41–
83 cm
2;P ,0.001). Patients with pre-MF had also lower
percentage of circulating immature myeloid cells and no patient
had circulating blasts at diagnosis. By using the International
Working Group prognostic classification [27], patients with pre-
MF displayed a greater frequency of zero-grade score than
patients with PMF-fibrotic type (91.3% vs. 51.7%; P=0.001). Pre-
MF patients showed a higher frequency of thrombotic events at
the time of diagnosis or in the year preceding the diagnosis than
patients with PMF-fibrotic type (30.3% vs. 6.7%; P,0.001)
(Table 2). Both in pre-MF and in PMF-fibrotic type, the great
majority of the thrombotic events was in splanchnic veins.
Biological Characteristics of Prefibrotic Myelofibrosis
As compared with patients with PMF-fibrotic type, those with
pre-MF had a statistically significant difference in the value of
biological parameters we measured as markers of disease activity
(Table 3). The greatest differences were obtained for CD34-
positive cells frequency and serum LDH value. By contrast,
neither the proportion of JAK2V617F mutated patients nor the
V617F allele burden was significantly different in patients with
pre-MF or PMF-fibrotic type. Cytogenetic findings at diagnosis
were abnormal in 13.8% of patients with pre-MF while they were
abnormal in 35.4% of patients with PMF-fibrotic type (P=0.034).
Determinants of Phenotypic Heterogeneity of Prefibrotic
Myelofibrosis
Hematological characteristics varied among patients with pre-
MF. Six out 79 (7.6%) female patients had hemoglobin greater
than 16.5 g/dL, the value WHO system uses for classifying PV
patients [11]. These patients received an original diagnosis of PV,
but polyglobulia spontaneously remitted early and the BM picture
was that of pre-MF. Sixty-nine percent of patients had more than
450610
9/L platelets, the value the WHO system uses for
classifying ET patients [11]. One patient had thrombocytopenia
(platelet count less than 150610
9/L), but the patient at the same
time suffered by portal vein thrombosis that could be the cause of
low platelet count. Three patients had white blood cell count equal
or greater than 25610
9/L, and 2 patients had white blood cell
count equal or lower than 4610
9/L.
By exploring the determinants of phenotypic heterogeneity at
diagnosis, we documented that female sex was associated with
Table 2. Major thrombotic events at diagnosis or in the year before diagnosis.
Prefibrotic myelofibrosis
(N=132)
Myelofibrosis fibrotic type
(N=551) P
Patients with thrombosis at diagnosis or in the year before diagnosis, N (%) 40 (30.3) 37 (6.7) 0.021
Type of thrombosis
Splanchnic vein thrombosis, N (%) 31 (77.5) 29 (78.4)
Budd-Chiari syndrome, N (%) 3 (7.5) 1 (2.7)
DVT-TE, N (%) 2 (5) 4 (10.8)
Arterial thrombosis, N (%) 2 (5) 3 (8.1)
Cerebral sinus thrombosis, N (%) 2 (5) 0 (0)
doi:10.1371/journal.pone.0035631.t002
Prefibrotic Myelofibrosis
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35631younger age (mean, 35.8 yrs vs. 41.9 yrs; P=0.003) and lower
hemoglobin (mean, 13.9 g/dL vs. 14.5 g/dL; P=0.028).
JAK2V617F mutation (either heterozygous or homozygous) was
associated with higher hemoglobin (mean, 14.4 vs. 13.5 g/dL;
P=0.004), lower platelet count (mean, 576 vs. 815610
9/L;
P,0.001), higher spleen index (mean, 124.8 vs. 103.9 cm
2;
P=0.006). Moreover, patients who carried a homozygous
mutation had significantly higher white-blood cell count than
those who either were wild-type or carried heterozygous mutation
(mean, 13.3 vs. 8.41610
9/L; P,0.001). Splanchnic vein throm-
bosis at diagnosis or in the year preceding the diagnosis was
associated with lower platelet count (mean, 374 vs. 716610
9/L;
P,0.001), larger spleen index (mean, 140 vs.114 cm
2; P=0.004),
and higher frequency of either heterozygous or homozygous
JAK2V617F mutation (86.2% vs. 59.5%; P=0.009).
Stepwise multiple regression analysis showed that JAK2V617F
mutational status and male sex were both significant determinants
of higher hemoglobin value (P=0.016 and 0.042, respectively).
Splanchnic vein thrombosis at diagnosis or in the year preceding
diagnosis was the only determinant of lower platelet count
(P=0.029). Finally, having splanchnic vein thrombosis at diagnosis
or in the year preceding the diagnosis and bearing JAK2V617F
mutation were both significant determinants of higher spleen
volume (P,0.001 and P=0.024, respectively).
Testing the Continuum Hypothesis
In order to test whether there was an underlying structure of
PMF patients’ characteristics that allowed to identify a continuum
along which pre-MF was aligned, we categorized PMF-fibrotic
type into two groups: PMF with early BM fibrosis (grade 1) and
with advanced BM fibrosis (grade 2 or 3). Table 1 reports the
clinical characteristics of these subgroups. A continuous modifica-
tion was observed for male to female ratio, age, hemoglobin,
platelet count and spleen size. However, only female to male ratio
significantly steadily decreased (P=0.03), while age steadily
increased (P=0.01) from pre-MF to PMF-fibrotic type with early
and advanced myelofibrosis (ANOVA for trend). On the contrary,
WBC did not differ among the three categories of patients and
Figure 1. Survival of patients with primary myelofibrosis.
Patients were categorized according they were diagnosed with
prefibrotic myelofibrosis, myelofibrosis-fibrotic type with early bone
marrow fibrosis (grade 1) or myelofibrosis-fibrotic type with advanced
bone marrow fibrosis (grade 2 or 3).
doi:10.1371/journal.pone.0035631.g001
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category of pre-MF.
CD34-positive cells in peripheral blood frequency and LDH
concentration increased along the continuum of BM fibrosis, while
CXCR4 expression and cholesterol level decreased (Table 3).
Only the values of LDH and CXCR4 expression showed a
significant trend (P=0.033 and P=0.003, respectively). Neither
the frequency of JAK2V617F mutation nor the mutation allele
burden changed among the three categories of patients.
Chromosomal aberrations steadily increased in frequency from
pre-MF to early to advanced BM-fibrosis subtypes of PMF-fibrotic
type. However, the trend was not statistically significant.
Course of the Disease
The whole cohort of patients with PMF was followed for a
median of 43 months (range, 1 to 375 months) after the diagnosis,
representing 3848 person-years. The median survival of the entire
cohort was 21 years. The cohort of patients with pre-MF was
followed for a median of 66 months (range, 1 to 371 months) after
the diagnosis. During 972 cumulative person-years of follow-up,
3.8% of patients with pre-MF died, while the proportion of
patients with PMF-fibrotic type who died was 20.8%. The cause of
death was blast transformation in 4 out 5 (80%) and 52 out 114
(45.6%), respectively. The median survival was not reached in pre-
MF, while it was 16.6 years in PMF-fibrotic type (P,0.001).
Ninety-eight, 81 and 56 percent of patients with pre-MF, PMF-
fibrotic type with early and PMF-fibrotic-type with advanced BM
fibrosis, respectively, were alive at 10 years from the diagnosis
(P,0.001)(Figure 1).
The progression of BM fibrosis was studied in 67 (50.7%)
patients with pre-MF. The 50% cumulative probability of
progression from fibrosis grade 0 to fibrosis grade 1 was reached
at 9.6 years and to fibrosis grade 2 or 3 at 16.4 years.
Discussion
By investigating a large data-base of consecutive patients with
PMF collected during a period of 21 years, we identified 132 cases
with pre-MF. In order to make our population of pre-MF patients
more homogenous and their distinction from PMF-fibrotic type
clearer, we relied on the diagnostic clear-cut feature of absence of
any degree of BM fibrosis. In this way, the possibility that the
claimed variability in the reading of BM samples could have
influenced our results still exists, but it should be minimal.
This study revealed that pre-MF possesses several epidemiolog-
ical and clinical features not previously come to light. In
comparison with patients with PMF-fibrotic type, the patients
with pre-MF were more likely to be female, to be under the age of
50 at diagnosis, to have a milder hematological and clinical
phenotype. Moreover, with the diagnosis of pre-MF we selected a
category of patients with very high frequency (30%) of coincidental
thrombotic events, mainly in splanchnic area. These results
underscore the importance of the effects of age and sex on the
phenotype of PMF, adding value to similar observations reported
in patients with PV and ET [27,28].
Despite the narrow criteria used for the diagnosis, our cases of
pre-MF displayed different hematological presentations. Seventy
percent of cases presented with an isolated thrombocytosis
simulating ET, and 30% were diagnosed in coincidence with
splanchnic vein thrombosis associated without any peripheral sign
of myeloproliferation. This latter presentation coincides with that
of masked MPNs associated with splanchnic vein thrombosis [29–
33], and in particular of the variant ‘‘atypical myeloproliferative
disorder with high thrombotic risk and slow disease progression’’
we first described in 1996 [34]. We documented that sex,
JAK2V617F mutation and presence of splanchnic vein thrombosis
were the most influential factors for the varying of phenotypes.
It resulted that the frequency of CD34-positive cells in
peripheral blood, CXCR4 expression on CD34-positive cells,
serum cholesterol and LDH levels were significantly different in
pre-MF as compared with PMF-fibrotic type. Cytogenetic analysis
confirmed that pre-MF is a less genetically unstable disease by
showing that pre-MF had significantly lower frequency of
chromosomal abnormalities as compared with PMF-fibrotic type.
We questioned whether it is justified to include pre-MF in the
realm of PMF, as claimed by the WHO classification system. We
documented that PMF-fibrotic type patients with an early or
advanced BM fibrosis were aligned with pre-MF to form three
categories of patients whose major epidemiological, clinical, and
biological characteristics steadily varied in a continuum. More-
over, the survival of the patients steadily decreased. We further
supported the contention that pre-MF is a prodromic phase of
PMF by showing in pre-MF patients a progressive accumulation of
reticulin fibers in the BM, thus documenting that transformation
in PMF-fibrotic type is part of the natural history of the disease.
The evidence that pre-MF is a prodromic phase of PMF makes
us more aware about the biology of the disease. Most of our cases
of pre-MF had increase in BM myeloproliferation with megakar-
yocyte hyperplasia and dysplasia as the sole biological deviation
from normal and many of them had thrombocytosis as the sole
hematologic alteration. This addresses to the idea that the initial
derangement of PMF could be restricted to megakaryopoiesis, and
that dysmegakaryopoiesis may occur without any bone marrow
fibrosis or hematopoietic progenitor cells mobilization, previously
considered specific biological markers of PMF.
The mechanism leading to high risk of splanchnic vein
thrombosis in the population of pre-MF is unknown. A result of
this study that could have pathogenetic relevance is the strict
association between JAK2V617F mutation and splanchnic vein
thrombosis. In fact, 82% of patients with splanchnic vein
thrombosis bore JAK2V617F mutation with respect to 59.5% of
patients without splanchnic vein thrombosis. This result addresses
to hypothesize that the cooperation of young age, female sex, and
JAK2V617F mutation could facilitate the development of a
thrombophilic environment in the splanchnic veins.
The evidence that pre-MF conforms to a continuum model has
a major implication for our knowledge on the overall clinical
characteristics of PMF. PMF is commonly described as the most
severe among MPNs, with median survival ranging from 4 to 10.6
years in modern series that did not include pre-MF [35–46]. In our
series, the median survival is 21 years, extremely longer than
previously reported. This is due primarily to pre-MF patients
which account for approximately 20% of the cases of PMF and
who bear a very good prognosis. However, our series contains a
large proportion of cases (30%) with PMF-fibrotic type with an
early BM fibrosis that contributes to prolong the mean survival of
the population. This drives to question on the real epidemiology of
the disease, and on how much selection and reporting biases could
influence the results of published series.
In conclusion, we have provided evidence that pre-MF is a
mode of presentation of PMF with an indolent phenotype and a
very long survival. Efforts to understand the natural history and to
improve prognosis prediction for PMF have in the past focused on
the population of patients with fibrotic type. Patients with pre-MF
clearly deserve similar attention.
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